AzTrials
AzTrials

Huntington DiseaseNCT02464293

A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease

A study testing Mindfulness-based cognitive therapy in people with Huntington Disease, run by Lancaster University at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a pilot study to see whether mindfulness-based cognitive therapy, which is a type of psychological therapy, is able to improve the psychological wellbeing of people who have the gene for Huntington's disease. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Huntington Disease
What is being tested?
Mindfulness-based cognitive therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
16 participants
Where
1 siteUnited Kingdom
Study dates
Jun 2015to 31 Jan 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • For those with HD:
  • Patient at Manchester Centre for Genomic Medicine (UK)
  • All participants will have had genetic testing and shown to have the requisite CAG expansion on the huntingtin gene.
  • Participants must be pre-symptomatic or at stage 1 (still able to function at home and at work and handle financial affairs)
  • Clinical sign of depression (score on HADS of 7 or above)
  • No significant medication changes in 6 weeks prior to starting the course
  • For those who are relatives or friends of those with HD:
  • Must be a relative or friend of someone participating in the MBCT course

Who cannot join

  • Active suicidal intent

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Central Manchester University Hospitals NHS Foundation Trust

    Manchester

Other trials in United Kingdom

About this study

This is a pilot study to see whether mindfulness-based cognitive therapy, which is a type of psychological therapy, is able to improve the psychological wellbeing of people who have the gene for Huntington's disease.

Read the detailed description

Huntingdon's disease (HD) is a genetic neurodegenerative condition which causes problems with movement, coordination and cognitive functioning, and emotional difficulties are also commonly experienced. It is believed to affect around five to ten in 100,000 people of European descent, with recent UK estimates as high as 11.2-13.5. Each child of an affected person has a 50% chance of inheriting the condition. As age of diagnosis is typically around 35-55, with time from diagnosis to death around 20 years, those who are diagnosed have often seen their parents affected by the condition.

Many people at various stages of HD (including those who carry the gene but are pre-symptomatic) experience low mood, anxiety and other psychological difficulties. Indeed, alongside functional capacity, mood may be one of the main factors which contributes to health related quality of life, more so than discrete motor problems, or cognitive impairment. In addition, reports from patients suggest emotional and social concerns are important for individuals with the condition at the pre-symptomatic stage, and these concerns remain throughout the disease course. Medication may be effective to alleviate psychological difficulties for some people, but its efficacy has not been conclusively proven and it is not suitable for all. Psychological interventions may provide an alternative or additional way of alleviating distress.

Although it is commonly presumed that biological factors are the main determinants of psychological distress in people with HD, several studies have indicated that, while these may indeed be important, psychological factors are also significant. For example beliefs about the disease and coping mechanisms are associated with poorer mental health and higher levels of depression. Such psychological beliefs and coping patterns can be adaptively changed using psychological interventions, for example cognitive-based psychological therapies.

Little progress has been reported on the development of psychological interventions in HD despite the fact that people with HD have expressed an interest in psychological approaches and these are currently being successfully developed for people with other neurological conditions (e.g., in people with Parkinson's disease). It is therefore proposed to pilot mindfulness-based cognitive therapy (MBCT) which, although originally developed to help people with remitted depression from relapse, has been increasingly used to help people with current difficulties. It has also been piloted with people with Parkinson's disease who found it an acceptable intervention and reported improvements in self-management and psychological wellbeing. In general, MBCT has also recorded other gains including improved sleep quality and social functioning. It has also received sufficient evidence for it to be a recommended approach in the UK NICE guidelines for people with a history of depression. MBCT can also reduce anxiety and provides group support. There are also indications that mindfulness training can improve neurocognitive functioning, even in people with neurodegenerative disease. Finally, a psychological therapy subgroup within the European Huntington's Disease Network has recently been formed, thus indicating the rise of interest in psychological approaches and the timely nature of this work.

Hence this study will provide the first indication of whether MBCT, a therapeutic approach with an established evidence base, would be acceptable and useful for people with HD. In order to meet this aim, MBCT will be delivered to two groups, one to individuals who carry the gene but are pre-symptomatic and one to individuals who have begun to experience symptoms but are at an early stage of the disease course.

Approaches to outcome evaluation should be incremental, with lower cost studies, e.g., qualitative investigations and case studies, being conducted before investment in randomised controlled trials is considered. Thus this study will follow this guidance by collecting both qualitative and quantitative data. The qualitative data will be analysed using interpretative phenomenological analysis, a methodology previously used in other qualitative studies on MBCT. Semi-structured interviews will provide data on the acceptability of the intervention and detailed accounts of participants' experience after the intervention has been provided. This will inform whether the MBCT intervention needs to be changed or adapted in further trials. The quantitative data will be used to provide basic pre and post intervention comparisons on a number of outcome variables relevant to MBCT, with the hypothesis that performance on these measures will improve post training. These data will also be used to estimate effect sizes for further trials so that these are suitably powered.

Given the considerable physical, cognitive and emotional consequences of the disease, HD not only affects the person with HD, but also those with whom they live, even in the pre-clinical phase. Family members often become caregivers and can have a reduced quality of life as a result, including experiencing low mood themselves. In fact, caregiver burden and caregiver depression is associated with depression of the person with HD and, alongside motor disturbances, depression of the person with HD is one of the main predictors of caregiver burden. Partners of people with HD can also experience reduced satisfaction with their relationship, sometimes more so than the person with HD themselves.

Thus this study will also investigate the views of a family member (e.g. partner, parent, child) of the person participating in the intervention. As the intervention is aimed at alleviating psychological distress in the person with HD, it is hypothesised that this in turn will also have an effect on the family member's wellbeing. Also, higher levels of mindfulness are associated with higher levels of satisfaction in partner relationships, perhaps due to more adaptive conflict resolution and better emotional recognition and management. Participants in MBCT have reported increased empathy and perspective taking, being more able to respond mindfully in relationships. Thus increased mindfulness of the person with HD may benefit family and social relationships.

In addition, caregivers' views about the symptoms or quality of life of the person with HD may not always match the person with HD themselves. Furthermore, certain symptom changes which are beneficial to the person with HD may not be so to the caregiver, and thus the caregiver can offer an alternative perspective of the wellbeing (including behavioural and psychological changes) of the person with HD.

Both qualitative and quantitative data will be collected from a family member or close friend of the person with HD, where such a person is available and willing to take part. Semi-structured interviews with the family member will explore their perceptions on the acceptability of the intervention and experiences of the person with HD, as well as the impact on the family member personally and the wider family system. Data collected pre and post the intervention will assess any changes in their psychological wellbeing, caregiver burden and family relationships, with the hypothesis that wellbeing and relationships will improve post training and caregiver burden will decrease.

Being tested
Mindfulness-based cognitive therapy
Keywords
depression, anxiety, stress
Medical subject headings
Huntington Disease, Depression, Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mindfulness-based cognitive therapyOther

    An 8 week course of mindfulness-based cognitive therapy

Study groups in NCT02464293
Study groupRoleWhat they receive
mindfulness-based cognitive therapyExperimentalNot described
Receives: Other: Mindfulness-based cognitive therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. depression post intervention

    Change in Hospital Anxiety and Depression Scale (HADS) depression score pre to post intervention (People with HD only)

    Measured: immediately post-intervention (up to two weeks afterwards)

  2. depression at 3 months

    Change in HADS depression score pre to 3 months post intervention

    Measured: 3 months post-intervention

  3. depression at 1 year

    Change in HADS depression score pre to 1 year post intervention

    Measured: 1 year post-intervention

Secondary outcomes (29)
  1. depression mid-course

    Change in HADS depression score pre to mid-course (4 weeks after start) (people with HD only)

    Measured: 4 weeks after start of intervention

  2. anxiety mid-course

    Change in HADS anxiety score pre to mid-course (4 weeks after start) (people with HD only)

    Measured: 4 weeks after start of intervention

  3. anxiety post intervention

    Change in HADS anxiety score pre to post-intervention (people with HD only)

    Measured: immediately post-intervention (up to two weeks afterwards)

  4. anxiety at 3 months

    Change in HADS anxiety score pre to 3 months post intervention

    Measured: 3 months post-intervention

  5. anxiety at 1 year

    Change in HADS anxiety score pre to 1 year post intervention

    Measured: 1 year post-intervention

  6. stress mid course

    Change in Depression Anxiety and Stress Scale (DASS) stress score pre to mid-course (4 weeks after start) (people with HD only)

    Measured: 4 weeks after start of intervention

  7. stress post intervention

    Change in DASS stress score pre to post course (people with HD only)

    Measured: immediately post-intervention (up to two weeks afterwards)

  8. stress at 3 months

    Change in DASS stress score pre to 3 months post intervention

    Measured: 3 months post-intervention

  9. stress at 1 year

    Change in DASS stress score pre to 1 year post intervention

    Measured: 1 year post-intervention

  10. mindfulness mid-course

    Change in Five Factor Mindfulness Questionnaire (FFMQ) score pre to mid-course (4 weeks after start) (people with HD only)

    Measured: 4 weeks after start of intervention

  11. mindfulness post intervention

    Change in FFMQ score pre to post course (people with HD only)

    Measured: immediately post-intervention (up to two weeks afterwards)

  12. mindfulness at 3 months

    Change in FFMQ score pre to 3 months post intervention

    Measured: 3 months post-intervention

  13. mindfulness at 1 year

    Change in FFMQ score pre to 1 year post intervention

    Measured: 1 year post-intervention

  14. sleep post intervention

    Change in Pittsburgh Sleep Quality Index (PSQI) score pre to post course (people with HD only)

    Measured: immediately post-intervention (up to two weeks afterwards)

  15. sleep at 3 months

    Change in PSQI score pre to 3 months post intervention (people with HD only)

    Measured: 3 months post-intervention

  16. sleep at 1 year

    Change in PSQI score pre to 1 year post intervention (people with HD only)

    Measured: 1 year post-intervention

  17. quality of life post intervention

    Change in World Health Organisation Quality of Life BREF) score (WHOQOL) pre to post course (people with HD only)

    Measured: immediately post-intervention (up to two weeks afterwards)

  18. quality of life at 3 months

    Change in WHOQOL score pre to 3 months post intervention

    Measured: 3 months post-intervention

  19. quality of life at 1 year

    Change in WHOQOL score pre to 1 year post intervention

    Measured: 1 year post-intervention

  20. positive affect post intervention

    Change in Positive And Negative Affect Scale (PANAS) positive items score pre to post course (people with HD only)

    Measured: immediately post-intervention (up to two weeks afterwards)

  21. positive affect at 3 months

    Change in PANAS positive items score pre to 3 months post intervention

    Measured: 3 months post-intervention

  22. positive affect at 1 year

    Change in PANAS positive items score pre to 1 year post intervention

    Measured: 1 year post-intervention

  23. coping post intervention

    Change in brief COPE score pre to post course (people with HD only)

    Measured: immediately post-intervention (up to two weeks afterwards)

  24. coping at 3 months

    Change in brief COPE score pre to 3 months post intervention

    Measured: 3 months post-intervention

  25. coping at 1 year

    Change in brief COPE score pre to 1 year post intervention

    Measured: 1 year post-intervention

  26. relationship satisfaction at 3 months

    Change in Relationship Assessment Scale (RAS) score pre to 3 months post intervention (relatives/friends only)

    Measured: 3 months post-intervention

  27. relationship satisfaction at 1 year

    Change in RAS score pre to 1 year post intervention (relatives/friends only)

    Measured: 1 year post-intervention

  28. carer burden at 3 months

    Change in carer burden inventory score pre to 3 months post intervention (relatives/friends only)

    Measured: 3 months post-intervention

  29. carer burden at 1 year

    Change in carer burden inventory score pre to 1 year post intervention (relatives/friends only)

    Measured: 1 year post-intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jun 2015 (estimated)
  2. Study startJun 2015
  3. Primary completion31 Jan 2018
  4. Study completion31 Jan 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
16 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02464293
Sponsor's protocol ID
EHDN Seed Fund Project 561
Other IDs
15/NW/0238
Status last verified
Jan 2020
First submitted
3 Jun 2015
Last updated
7 Jan 2020
Results posted
No
Data monitoring committee
No

Publications

  • Arran N, Craufurd D, Simpson J. Illness perceptions, coping styles and psychological distress in adults with Huntington's disease. Psychol Health Med. 2014;19(2):169-79. doi: 10.1080/13548506.2013.802355. Epub 2013 Jun 14.

    PubMed 23767964
  • Aoun, S, Kristjanson, L, Oldham, L.The Challenges and Unmet Needs of People with Neurodegenerative Conditions and their Carers. Journal for Community Nurses, 11(1): 17-20, 2006.

  • Aubeeluck A, Buchanan H. The Huntington's disease quality of life battery for carers: reliability and validity. Clin Genet. 2007 May;71(5):434-45. doi: 10.1111/j.1399-0004.2007.00784.x.

    PubMed 17489849
  • Aubeeluck AV, Buchanan H, Stupple EJ. 'All the burden on all the carers': exploring quality of life with family caregivers of Huntington's disease patients. Qual Life Res. 2012 Oct;21(8):1425-35. doi: 10.1007/s11136-011-0062-x. Epub 2011 Nov 13.

    PubMed 22081218
  • Banaszkiewicz K, Sitek EJ, Rudzinska M, Soltan W, Slawek J, Szczudlik A. Huntington's disease from the patient, caregiver and physician's perspectives: three sides of the same coin? J Neural Transm (Vienna). 2012 Nov;119(11):1361-5. doi: 10.1007/s00702-012-0787-x. Epub 2012 Mar 8.

    PubMed 22398875
  • Barnes S, Brown KW, Krusemark E, Campbell WK, Rogge RD. The role of mindfulness in romantic relationship satisfaction and responses to relationship stress. J Marital Fam Ther. 2007 Oct;33(4):482-500. doi: 10.1111/j.1752-0606.2007.00033.x.

    PubMed 17935531
  • Barnhofer T, Crane C, Hargus E, Amarasinghe M, Winder R, Williams JM. Mindfulness-based cognitive therapy as a treatment for chronic depression: A preliminary study. Behav Res Ther. 2009 May;47(5):366-73. doi: 10.1016/j.brat.2009.01.019. Epub 2009 Feb 5.

    PubMed 19249017
  • Bihari, J, Mullan, E. Relating Mindfully: A Qualitative Exploration of Changes in Relationships Through Mindfulness-Based Cognitive Therapy. Mindfulness 5(1): 46-59, 2014.

  • Cairns V, Murray C. How do the features of mindfulness-based cognitive therapy contribute to positive therapeutic change? A meta-synthesis of qualitative studies. Behav Cogn Psychother. 2015 May;43(3):342-59. doi: 10.1017/S1352465813000945. Epub 2013 Nov 11.

    PubMed 24229765
  • Craufurd, D, Snowden, JS. Neuropsychiatry and Neuropsychology. In G Bates, SJ Tabrizi, L Jones (Eds.), Huntington's disease (4th ed., pp. 36-65). Oxford: Oxford University Press. (2014)

  • Craufurd D, Thompson JC, Snowden JS. Behavioral changes in Huntington Disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001 Oct-Dec;14(4):219-26.

    PubMed 11725215
  • Dobkin RD, Menza M, Allen LA, Gara MA, Mark MH, Tiu J, Bienfait KL, Friedman J. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J Psychiatry. 2011 Oct;168(10):1066-74. doi: 10.1176/appi.ajp.2011.10111669. Epub 2011 Jun 15.

    PubMed 21676990
  • Eisendrath SJ, Delucchi K, Bitner R, Fenimore P, Smit M, McLane M. Mindfulness-based cognitive therapy for treatment-resistant depression: a pilot study. Psychother Psychosom. 2008;77(5):319-20. doi: 10.1159/000142525. Epub 2008 Jul 4. No abstract available.

    PubMed 18600038
  • Evans SJ, Douglas I, Rawlins MD, Wexler NS, Tabrizi SJ, Smeeth L. Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1156-60. doi: 10.1136/jnnp-2012-304636. Epub 2013 Mar 12.

    PubMed 23482661
  • Fitzpatrick L, Simpson J, Smith A. A qualitative analysis of mindfulness-based cognitive therapy (MBCT) in Parkinson's disease. Psychol Psychother. 2010 Jun;83(Pt 2):179-92. doi: 10.1348/147608309X471514. Epub 2009 Oct 19.

    PubMed 19843353

Questions about this trial

What is this clinical trial studying?

A study testing Mindfulness-based cognitive therapy in people with Huntington Disease, run by Lancaster University at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

depression post intervention (time frame: immediately post-intervention (up to two weeks afterwards)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02464293, which also lists 47 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in